International Journal of Clinical Research. 2021; 5: (2) ; 10.12208/j.ijcr.20210016.
目的 评价尤瑞克林联合丹参酮IIA治疗急性脑梗死的临床效果。方法 选择2018年1月~2020年2月50例急性脑梗死（ACI）患者，随机均分为观察组和对照组。两组均采用降低颅内压、神经保护剂、改善微循环、抗感染等基础治疗，对照组给予尤瑞克林0.15PNAU/次，qd，观察组给予尤瑞克林0.15PNAU/次，qd，联合丹参酮IIA 60mg/次，qd，两组均治疗2w。比较两组神经功能（神经功能缺损-NIHSS评分）和日常生活能力（ADL评分），观察两组疗效和炎性因子（IL-6、TNF-α）变化。结果 观察组NIHSS评分明显低于对照组（P<0.05），ADL评分显著高于对照组（P<0.05）。观察组治疗有效率为100.00%，显著高于对照组的72.00%（P<0.05）。观察组IL-6、TNF-α明显低于对照组（P<0.05）。结论 尤瑞克林联合丹参酮IIA明显改善ACI患者的神经功能，提高日常生活能力和疗效，抑制炎性反应。
Objective To evaluate the clinical effect of urinary kallid combined with tanshinone IIA in the treatment of acute cerebral infarction. Methods: 50 patients with acute cerebral infarction (ACI), selected from January 2018 to February 2020, were randomly divided into the observation group and the control group,25 cases in each group. Patients were received reducing intracranial pressure,neuroprotection, improving microcirculation and anti-infection therapy in the two groups. Patients in the control group were given urinary kallid 0.15PNAU/times,qd, patients in the observation group were received urinary kallid 0.15PNAU/time combined with tanshinone IIA 60mg/time,qd respectively. The therapy would be two weeks in each group. The neurologic impairment(NIHSS scores) and ability of activities of daily living (ADL scores) were compared in the two groups. The curative effect and the changes of inflammatory factors (IL-6,TNF-α) were observed in the two groups. Results: NIHSS scores in the observation group were significantly lower than those in the control group (P<0.05), and ADL scores in the observation group were significantly higher than those in the control group (P<0.05). The effective rate in the observation group was 100.00%, which was significantly higher than that (72.00%) in the control group (P<0.05). IL-6 and TNF-α in the observation group were significantly lower than those in the control group (P<0.05). Conclusion : Urinary kallid combined with tanshinone IIA could significantly improve neurological function, improve the ability of daily living andefficacy, inhibit the inflammatory response in patients with ACI.